My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 134

    1.

    1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.

    Berl T, Berns AS, Hufer WE, Hammill K, Alfrey AC, Arnaud CD, Schrier RW.

    Ann Intern Med. 1978 Jun;88(6):774-80.PMID: 208439 [PubMed - indexed for MEDLINE]Related articles

    2.

    Controlled trial of the effects of 1,25-dihydroxycholecalciferol in patients treated with regular dialysis.

    Berl T, Berns AS, Huffer WE, Alfrey AC, Arnaud CD, Schrier RR.

    Contrib Nephrol. 1980;18:72-81.PMID: 6243528 [PubMed - indexed for MEDLINE]Related articles

    3.

    Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure.

    Christiansen C, Røodbro P, Christensen MS, Naestoft J, Hartnack B, Transbøol I.

    Contrib Nephrol. 1980;18:139-46.PMID: 6243527 [PubMed - indexed for MEDLINE]Related articles

    4.

    The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.

    Bordier P, Zingraff J, Gueris J, Jungers P, Marie P, Pechet M, Rasmussen H.

    Am J Med. 1978 Jan;64(1):101-7.PMID: 623125 [PubMed - indexed for MEDLINE]Related articles

    5.

    Calcitriol in dialysis patients.

    Maxwell DR, Benjamin DM, Donahay SL, Allen MK, Hamburger RJ, Luft FC.

    Clin Pharmacol Ther. 1978 May;23(5):515-9.PMID: 205382 [PubMed - indexed for MEDLINE]Related articles

    6.

    Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol.

    Christiansen C, Rødbro P, Christensen MS, Hartnack B, Transbøl I.

    Lancet. 1978 Sep 30;2(8092 Pt 1):700-3.PMID: 80633 [PubMed - indexed for MEDLINE]Related articles

    7.

    Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.

    Massry SG, Goldstein DA, Malluche HH.

    Kidney Int. 1980 Oct;18(4):409-18. Review. No abstract available. PMID: 7014981 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effects of 1,25-dihydroxyvitamin-D3 treatment on mineral balance in children with end stage renal disease undergoing chronic hemofiltration.

    Bettinelli A, Bianchi ML, Aimini E, Ortolani S, Soldati L, Edefonti A.

    Pediatr Res. 1986 Jan;20(1):5-8.PMID: 3753754 [PubMed - indexed for MEDLINE]Related articles

    9.

    Long-term therapy of uremic osteodystrophy in adults with calcitriol.

    Moorthy AV, Harrington AR, Mazess RB, Simpson DP.

    Clin Nephrol. 1981 Aug;16(2):93-100.PMID: 6894893 [PubMed - indexed for MEDLINE]Related articles

    10.

    Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.

    Dunstan CR, Hills E, Norman AW, Bishop JE, Mayer E, Wong SY, Eade Y, Johnson JR, George CR, Collett P, et al.

    Miner Electrolyte Metab. 1985;11(6):358-68.PMID: 3877862 [PubMed - indexed for MEDLINE]Related articles

    11.

    L-alpha-hydroxycholecalciferol treatment of adults with chronic renal failure.

    Madsen S, Olgaard K.

    Acta Med Scand. 1976;200(1-2):1-5.PMID: 961464 [PubMed - indexed for MEDLINE]Related articles

    12.

    The effect of hemodialysis, vitamin D metabolites and renal transplantation on the skeletal demineralization associated with renal osteodystrophy: a computerized histomorphometric analysis.

    Main J, Velasco N, Catto GR, Fraser RA, Edward N, Adami S, O'Riordan JL.

    Clin Nephrol. 1986 Dec;26(6):279-87.PMID: 3542321 [PubMed - indexed for MEDLINE]Related articles

    13.

    A possible direct effect of 24,25-dihydroxycholecalciferol on the parathyroid gland in patients with chronic renal failure.

    Christiansen C, Rødbro P, Naestoft J, Christensen MS.

    Clin Endocrinol (Oxf). 1981 Sep;15(3):237-42.PMID: 6273028 [PubMed - indexed for MEDLINE]Related articles

    14.

    Vitamin D metabolism and parathyroid function in man.

    Mawer EB, Backhouse J, Hill LF, Lumb GA, De Silva P, Taylor CM, Stanbury SW.

    Clin Sci Mol Med. 1975 May;48(5):349-65.PMID: 165031 [PubMed - indexed for MEDLINE]Related articles

    15.

    24,25-dihydroxy vitamin D3 treatment inhibits parathyroid-stimulated adenylate cyclase in iliac crest biopsies from uremic patients.

    Mortensen BM, Aarseth HP, Ganss R, Haug E, Gautvik KM, Gordeladze JO.

    Bone. 1993 Mar-Apr;14(2):125-31.PMID: 8334029 [PubMed - indexed for MEDLINE]Related articles

    16.

    Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients.

    Popovtzer MM, Levi J, Bar-Khayim Y, Shasha SM, Boner G, Bernheim J, Chaimovitz C, Rubinger D, Gafter U, Gazit D, et al.

    Bone. 1992;13(5):369-77.PMID: 1419378 [PubMed - indexed for MEDLINE]Related articles

    17.

    Chronic renal failure and vitamin D metabolites: a status report.

    Christiansen C.

    J Steroid Biochem. 1983 Jul;19(1B):517-23.PMID: 6310241 [PubMed - indexed for MEDLINE]Related articles

    18.

    Comparative therapeutic effects of vitamin D3 and its derivatives on experimental renal osteodystrophy.

    Fukushima M, Niki R, Ohkawa H, Shimizu T, Matsunaga I, Nakano H, Takagaki Y, Nishii Y, Okano K, Suda T.

    Endocrinology. 1980 Jul;107(1):328-33.PMID: 6247140 [PubMed - indexed for MEDLINE]Related articles

    19.

    Experience with 1,25-dihydroxycholecalciferol therapy in undergoing hemodialysis patients with progressive vitamin D2-treated osteodystrophy.

    Prior JC, Cameron EC, Ballon HS, Lirenman DS, Moriarty MV, Price JD.

    Am J Med. 1979 Oct;67(4):583-9.PMID: 386792 [PubMed - indexed for MEDLINE]Related articles

    20.

    Hemodialysis patients with a unique mineralizing defect unresponsive to 1,25-dihydroxycholecalciferol. Dialysis osteomalacic syndrome.

    Cameron EC, Prior JC, Ballon HS.

    Contrib Nephrol. 1980;18:162-71.PMID: 6986229 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity